Sugi Predict

Sugi Predict / Targets / NADK

NADK

NAD kinase · O95544 · NADK on Sugi Atlas →

4,449 patent compounds predicted against NADK, 4,011 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL952553 SCHEMBL952553 0.66 3/20
SCHEMBL952554 SCHEMBL952554 0.66 3/20
SCHEMBL952181 SCHEMBL952181 0.80 2/20
SCHEMBL952182 SCHEMBL952182 0.80 2/20
SCHEMBL440925 SCHEMBL440925 0.79 2/20
SCHEMBL440926 SCHEMBL440926 0.79 2/20
SCHEMBL1106674 SCHEMBL1106674 0.79 2/20
Adenosine Triphosphate Adenosine Triphosphate (SCHEMBL811698) 0.74 2/20
Adenosine Diphosphate Adenosine Diphosphate (SCHEMBL570243) 0.73 2/20
Adenosine Phosphate Adenosine Phosphate (SCHEMBL160972) 0.68 2/20
SCHEMBL1740341 SCHEMBL1740341 0.61 2/20
SCHEMBL1144664 SCHEMBL1144664 0.60 2/20
SCHEMBL1144665 SCHEMBL1144665 0.60 2/20
SCHEMBL4595394 SCHEMBL4595394 0.60 2/20
SCHEMBL952452 SCHEMBL952452 0.59 2/20
SCHEMBL952454 SCHEMBL952454 0.59 2/20
Adenine Adenine (SCHEMBL15279) 0.58 2/20
Adenine Adenine (SCHEMBL851383) 0.58 2/20
SCHEMBL3701954 SCHEMBL3701954 0.57 2/20
SCHEMBL3704527 SCHEMBL3704527 0.57 2/20

Clinical trials — most relevant to NADK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis PHASE4NOT_YET_RECRUITING
cindilizumab + Bevacizumab + Coenzyme I for Injection in Unresectable Hepatocellular Carcinoma PHASE4UNKNOWN
Cardiotoxicity in Breast Cancer Patients PHASE4RECRUITING
The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus PHASE3COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia PHASE2COMPLETED
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome PHASE1/PHASE2COMPLETED
A Study to Assess APO866 for the Treatment of Advanced Melanoma PHASE2COMPLETED
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly PHASE2WITHDRAWN
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration PHASE2COMPLETED
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults PHASE2RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype PHASE2UNKNOWN
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy PHASE1COMPLETED
Effects of Protein Hydrolysate Supplement on Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects nanCOMPLETED
Sirtuin1 in COVID19 Patients nanUNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Nicotinamide Riboside Clinical Trial for GWI nanRECRUITING
NR Supplementation and Exercise nanCOMPLETED
Project SIRT6 Activator nanRECRUITING
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery nanNOT_YET_RECRUITING
The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition nanCOMPLETED
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels nanRECRUITING
Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension nanRECRUITING
Chronic Mesenteric Ischemia Breath Testing nanCOMPLETED
Multi-omics Study in Citrin Deficiency nanACTIVE_NOT_RECRUITING
Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men nanCOMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+) nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NADK binder may also engage these)

ProteinNameSimilarity
P58058 — 0.988 P58058 →
D3Z7P3 — 0.939 D3Z7P3 →
Q91YD4 — 0.938 Q91YD4 →
Q9ULP0 — 0.936 Q9ULP0 →
GLS Glutaminase kidney isoform, mitochondrial 0.936 landscape →
Q9UGV2 — 0.935 Q9UGV2 →
P13264 — 0.935 P13264 →
Q4R766 — 0.935 Q4R766 →
A7MB28 — 0.935 A7MB28 →
Q6AYR2 — 0.933 Q6AYR2 →
E9PTA2 — 0.933 E9PTA2 →
Q9Z2L9 — 0.932 Q9Z2L9 →
Q8TCT0 — 0.932 Q8TCT0 →
Q5ZHN3 — 0.931 Q5ZHN3 →
Q5RA95 — 0.931 Q5RA95 →
Q8BTG7 — 0.931 Q8BTG7 →
TRPM2 Transient receptor potential cation channel subfamily M member 2 0.930 landscape →
KCNT2 Potassium channel subfamily T member 2 0.930 landscape →
Q09LZ8 — 0.930 Q09LZ8 →
B0VX69 — 0.929 B0VX69 →
O43502 — 0.929 O43502 →
Q99K70 — 0.929 Q99K70 →
Q5PYH5 — 0.929 Q5PYH5 →
Q7ZWU5 — 0.928 Q7ZWU5 →
ABHD12 Lysophosphatidylserine lipase ABHD12 0.928 landscape →
Q6AYT7 — 0.928 Q6AYT7 →
Q9QYF9 — 0.928 Q9QYF9 →
DHX9 ATP-dependent RNA helicase A 0.928 landscape →
Q91987 — 0.928 Q91987 →
P20595 — 0.928 P20595 →